

NEWPORT CORP  
Form 10-Q  
November 12, 2015  
[Table of Contents](#)

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

---

**FORM 10-Q**

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended October 3, 2015

OR

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number: 000-01649

## NEWPORT CORPORATION

(Exact name of registrant as specified in its charter)

**Nevada**  
(State or other jurisdiction of  
incorporation or organization)

**94-0849175**  
(IRS Employer Identification No.)

**1791 Deere Avenue, Irvine, California 92606**

(Address of principal executive offices) (Zip Code)

**(949) 863-3144**

(Registrant's telephone number, including area code)

**Not Applicable**

(Former name, former address and former fiscal year, if changed since last report)

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes  No

## Edgar Filing: NEWPORT CORP - Form 10-Q

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large accelerated filer  Accelerated filer   
Non-accelerated filer  (Do not check if a smaller reporting company) Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes  No

As of October 30, 2015, 38,576,708 shares of the registrant's sole class of common stock were outstanding.

---

Table of Contents

**NEWPORT CORPORATION**

**FORM 10-Q**

**INDEX**

|  | <b>Page<br/>Number</b> |
|--|------------------------|
| <b><u>PART I. FINANCIAL INFORMATION</u></b>  |                        |
| <u>Item 1.</u>   |                        |
| <u>Financial Statements (unaudited):</u>   |                        |
| <u>Consolidated Statements of Income and Comprehensive Income for the Three and<br/>        Nine Months Ended October 3, 2015 and September 27, 2014</u> | 3                      |
| <u>Consolidated Balance Sheets as of October 3, 2015 and January 3, 2015</u>   | 4                      |
| <u>Consolidated Statements of Cash Flows for the Nine Months Ended October 3, 2015<br/>        and September 27, 2014</u>                                | 5                      |
| <u>Notes to Consolidated Financial Statements</u>  | 6                      |
| <u>Item 2.</u>   |                        |
| <u>Management's Discussion and Analysis of Financial Condition and Results of<br/>    Operations</u>   | 18                     |
| <u>Item 3.</u>   |                        |
| <u>Quantitative and Qualitative Disclosures About Market Risk</u>  | 26                     |
| <u>Item 4.</u>   |                        |
| <u>Controls and Procedures</u>   | 28                     |
| <b><u>PART II. OTHER INFORMATION</u></b>   |                        |
| <u>Item 1A.</u>  |                        |
| <u>Risk Factors</u>  | 29                     |
| <u>Item 2.</u>   |                        |
| <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>   | 29                     |
| <u>Item 6.</u>   |                        |
| <u>Exhibits</u>  | 30                     |
| <b><u>SIGNATURES</u></b>   | 31                     |

Table of Contents**PART I FINANCIAL INFORMATION****ITEM 1. FINANCIAL STATEMENTS****NEWPORT CORPORATION****Consolidated Statements of Income and Comprehensive Income****(In thousands, except per share data)****(Unaudited)**

|   | Three Months Ended |                       | Nine Months Ended  |                       |
|---|--------------------|-----------------------|--------------------|-----------------------|
|   | October 3,<br>2015 | September 27,<br>2014 | October 3,<br>2015 | September 27,<br>2014 |
| Net sales   | \$ 147,560         | \$ 146,299            | \$ 452,192         | \$ 446,421            |
| Cost of sales   | 85,133             | 80,334                | 255,565            | 245,109               |
| Gross profit  | 62,427             | 65,965                | 196,627            | 201,312               |
| Selling, general and administrative expense                               | 37,730             | 39,122                | 117,029            | 120,413               |
| Research and development expense  | 14,232             | 14,082                | 44,345             | 42,538                |
| Loss (gain) on sale or other disposal of assets,<br>net                   |                    |                       | 1,088              | (411)                 |
| Operating income  | 10,465             | 12,761                | 34,165             | 38,772                |
| Interest and other expense, net   | (1,353)            | (958)                 | (3,320)            | (2,592)               |
| Income before income taxes  | 9,112              | 11,803                | 30,845             | 36,180                |
| Income tax provision  | 2,009              | 2,330                 | 9,308              | 9,769                 |
| Net income  | 7,103              | 9,473                 | 21,537             | 26,411                |
| Net income attributable to non-controlling<br>interests                   |                    | 3                     |                    | 103                   |
| Net income attributable to Newport Corporation                            | \$ 7,103           | \$ 9,470              | \$ 21,537          | \$ 26,308             |
| Net income  | \$ 7,103           | \$ 9,473              | \$ 21,537          | \$ 26,411             |
| Other comprehensive income (loss):  |                    |                       |                    |                       |
| Foreign currency translation gains (losses)                               | 673                | (7,203)               | (5,290)            | (7,567)               |
| Unrecognized net pension gains, net of tax                                | 79                 | 204                   | 508                | 306                   |
| Unrealized losses on investments and<br>marketable securities, net of tax | (13)               | (155)                 | (122)              | (177)                 |
| Other comprehensive income (loss)   | 739                | (7,154)               | (4,904)            | (7,438)               |
| Comprehensive income  | \$ 7,842           | \$ 2,319              | \$ 16,633          | \$ 18,973             |
| Comprehensive (loss) income attributable to<br>non-controlling interests  | \$                 | \$ (5)                | \$                 | \$ 110                |
| Comprehensive income attributable to Newport<br>Corporation               | 7,842              | 2,324                 | 16,633             | 18,863                |
| Comprehensive income  | \$ 7,842           | \$ 2,319              | \$ 16,633          | \$ 18,973             |

Edgar Filing: NEWPORT CORP - Form 10-Q

Net income per share attributable to Newport

Corporation:

|         |    |      |    |      |    |      |    |      |
|---------|----|------|----|------|----|------|----|------|
| Basic   | \$ | 0.18 | \$ | 0.24 | \$ | 0.55 | \$ | 0.66 |
| Diluted | \$ | 0.18 | \$ | 0.23 | \$ | 0.54 | \$ | 0.65 |

Shares used in per share calculations:

|         |        |        |        |        |
|---------|--------|--------|--------|--------|
| Basic   | 38,982 | 39,921 | 39,434 | 39,776 |
| Diluted | 39,374 | 40,612 | 40,066 | 40,546 |

The accompanying notes are an integral part of these financial statements.

Table of Contents

## NEWPORT CORPORATION

## Consolidated Balance Sheets

(In thousands, except share and per share data)

(Unaudited)

|  | October 3,<br>2015 | January 3,<br>2015 |
|--|--------------------|--------------------|
| <b>ASSETS</b>  |                    |                    |
| Current assets:  |                    |                    |
| Cash and cash equivalents  | \$ 30,440          | \$ 46,883          |
| Restricted cash  | 974                | 1,704              |
| Marketable securities  |                    | 57                 |
| Accounts receivable, net of allowance for doubtful accounts of \$1,297 and \$1,242 as of October 3, 2015 and January 3, 2015, respectively   | 103,714            | 96,512             |
| Inventories  | 122,845            | 112,440            |
| Current deferred tax assets  | 20,606             | 20,734             |
| Prepaid expenses and other current assets  | 18,294             | 14,948             |
| Total current assets   | 296,873            | 293,278            |
| Property and equipment, net  | 84,362             | 82,793             |
| Goodwill   | 103,854            | 97,524             |
| Long-term deferred tax assets  | 6,049              | 5,005              |
| Intangible assets, net   | 68,228             | 70,811             |
| Investments and other assets   | 28,486             | 30,516             |
| Total assets   | \$ 587,852         | \$ 579,927         |
| <b>LIABILITIES AND STOCKHOLDERS EQUITY</b>   |                    |                    |
| Current liabilities:   |                    |                    |
| Short-term borrowings  | \$ 3,579           | \$ 3,772           |
| Accounts payable   | 31,281             | 31,448             |
| Accrued payroll and related expenses   | 31,890             | 34,607             |
| Accrued expenses and other current liabilities   | 30,785             | 31,797             |
| Total current liabilities  | 97,535             | 101,624            |
| Long-term debt   | 84,254             | 71,000             |
| Pension liabilities  | 29,432             | 28,554             |
| Long-term deferred tax liabilities   | 14,119             | 14,272             |
| Other long-term liabilities  | 6,881              | 7,773              |
| Commitments and contingencies  |                    |                    |
| Stockholders equity:   |                    |                    |
| Common stock, par value \$0.1167 per share, 200,000,000 shares authorized; 38,576,708 and 39,603,662 shares issued and outstanding as of October 3, 2015 and January 3, 2015, respectively | 4,506              | 4,626              |
| Capital in excess of par value   | 450,989            | 468,575            |
| Accumulated other comprehensive loss   | (22,886)           | (17,982)           |
| Accumulated deficit  | (76,978)           | (98,515)           |
| Total stockholders equity  | 355,631            | 356,704            |
| Total liabilities and stockholders equity  | \$ 587,852         | \$ 579,927         |

Edgar Filing: NEWPORT CORP - Form 10-Q

The accompanying notes are an integral part of these financial statements.



Table of Contents

## NEWPORT CORPORATION

## Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

|   | Nine Months Ended  |                       |
|---|--------------------|-----------------------|
|   | October 3,<br>2015 | September 27,<br>2014 |
| <b>CASH FLOWS FROM OPERATING ACTIVITIES:</b>  |                    |                       |
| Net income  | \$ 21,537          | \$ 26,411             |
| Adjustments to reconcile net income to net cash provided by operating activities:   |                    |                       |
| Depreciation and amortization   | 21,363             | 22,271                |
| Gain on sale of assets  |                    | (411)                 |
| Provision for losses on inventories   | 6,115              | 4,429                 |
| Stock-based compensation expense  | 10,058             | 8,588                 |
| Provision for doubtful accounts   | 225                | 585                   |
| Loss on disposal of property and equipment  | 1,158              | 370                   |
| Deferred income taxes   | (897)              | (929)                 |
| Excess tax benefits from stock-based compensation                                   | (2,596)            | (4,403)               |
| Increase (decrease) in cash, net of acquisition and divestiture, due to changes in: |                    |                       |
| Accounts receivable   | (6,950)            | (7,576)               |
| Inventories   | (15,992)           | (20,183)              |
| Prepaid expenses and other assets   | (345)              | 27                    |
| Accounts payable  | (3,105)            | 3,763                 |
| Accrued payroll and related expenses  | (3,497)            | 2,569                 |
| Accrued expenses and other liabilities  | 816                | 4,447                 |
| Other long-term liabilities   | 490                | (977)                 |
| Net cash provided by operating activities   | 28,380             | 38,981                |
| <b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>  |                    |                       |
| Purchase of property and equipment  | (15,511)           | (17,993)              |
| Restricted cash   | 661                | 600                   |
| Proceeds from divestiture of business   |                    | 5,030                 |
| Acquisition of business, net of cash acquired                                       | (7,865)            |                       |
| Refundable amounts related to acquisition of a business                             | (2,319)            |                       |
| Purchase of investments and marketable securities                                   | (1,139)            | (1,414)               |
| Proceeds from the sale or maturity of investments and marketable securities         | 281                | 8,509                 |
| Net cash used in investing activities   | (25,892)           | (5,268)               |
| <b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>  |                    |                       |
| Proceeds from long-term debt  | 28,000             | 4,000                 |
| Repayment of long-term debt and obligations under capital leases                    | (15,012)           | (20,200)              |
| Proceeds from short-term borrowings   | 1,916              | 5,766                 |
| Repayment of short-term borrowings  | (6,123)            | (5,635)               |
| Purchases of non-controlling interests  |                    | (1,863)               |
| Proceeds from the issuance of common stock under employee plans                     | 1,353              | 4,156                 |
| Tax withholding payments related to net share settlement of equity awards           | (3,419)            | (2,940)               |
| Purchases of the Company's common stock   | (27,893)           | (4,480)               |
| Excess tax benefits from stock-based compensation                                   | 2,596              | 4,403                 |
| Net cash used in financing activities   | (18,582)           | (16,793)              |

Edgar Filing: NEWPORT CORP - Form 10-Q

|  |    |          |    |         |
|--|----|----------|----|---------|
| Impact of foreign exchange rate changes on cash balances |    | (349)    |    | (1,650) |
| Net (decrease) increase in cash and cash equivalents     |    | (16,443) |    | 15,270  |
| Cash and cash equivalents at beginning of period         |    | 46,883   |    | 53,710  |
| Cash and cash equivalents at end of period               | \$ | 30,440   | \$ | 68,980  |
| Supplemental disclosures of cash flow information:       |    |          |    |         |
| Cash paid during the period for interest                 | \$ | 1,498    | \$ | 1,490   |
| Cash paid during the period for income taxes, net        | \$ | 7,003    | \$ | 4,065   |
| Property and equipment accrued in accounts payable       | \$ | 292      | \$ | 123     |

The accompanying notes are an integral part of these financial statements.

Table of Contents

**NEWPORT CORPORATION**

**Notes to Consolidated Financial Statements**

**October 3, 2015**

**NOTE 1 BASIS OF PRESENTATION**

The accompanying unaudited consolidated financial statements include the accounts of Newport Corporation and its subsidiaries (collectively referred to as the Company) and have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions of Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, all adjustments (consisting of normal and recurring accruals) considered necessary for a fair presentation have been included. All intercompany transactions and balances have been eliminated in consolidation.

The accompanying unaudited consolidated financial statements do not include certain footnotes and financial presentations normally required under generally accepted accounting principles (GAAP) and, therefore, should be read in conjunction with the consolidated financial statements and related notes contained in the Company's Annual Report on Form 10-K for the year ended January 3, 2015. The results for the interim periods are not necessarily indicative of the results the Company will have for the full year ending January 2, 2016. The January 3, 2015 balances reported herein are derived from the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended January 3, 2015.

**NOTE 2 RECENT ACCOUNTING PRONOUNCEMENTS**

In September 2015, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2015-16, *Simplifying the Accounting for Measurement Period Adjustments*. ASU No. 2015-16 requires an acquirer in a business combination to recognize adjustments to the provisional amounts that are identified during the measurement period to be reported in the period in which the adjustment amounts are determined. In addition, the effect on earnings of changes in depreciation or amortization, or other income effects (if any) as a result of the change to the provisional amounts, calculated as if the accounting had been completed as of the acquisition date, must be recorded in the reporting period in which the adjustment amounts are determined. ASU No. 2015-16 will be effective for fiscal years and interim periods beginning after December 15, 2015, and is required to be applied prospectively. Early adoption is permitted for financial statements that have not been issued prior to the effective date of this update. The Company's adoption of ASU No. 2015-16 is not expected to have a material impact on the Company's financial position or results of operations.

**NOTE 3 ACQUISITION OF FEMTOLASERS**

On February 11, 2015, the Company acquired all of the capital stock of FEMTOLASERS Produktions GmbH (FEMTOLASERS). The initial purchase price of \$9.1 million was paid in cash at closing and is subject to a net asset adjustment. The Company has estimated a net asset adjustment of \$2.1 million, resulting in a purchase price of \$7.0 million (approximately \$7.9 million). The final amount of this net asset

## Edgar Filing: NEWPORT CORP - Form 10-Q

adjustment is currently under negotiation between the Company and the FEMTOLASERS selling shareholders. Of the initial purchase price, 2.3 million was deposited at closing into escrow until 30 months after closing, to secure certain obligations of the FEMTOLASERS selling shareholders under the share purchase agreement, including the net asset adjustment. The Company incurred \$0.4 million in transaction costs, which have been expensed as incurred and are included in *selling, general and administrative expense* in the statements of income and comprehensive income. FEMTOLASERS expands the Company's offering of ultrafast laser products and enhances its technology base in this area. The results of FEMTOLASERS have been included in the results of the Company's Lasers Group as of the acquisition date.

Immediately following the closing of the acquisition, the Company repaid 3.6 million (approximately \$4.0 million) of FEMTOLASERS outstanding loans that were assumed as part of the acquisition.

The consideration paid by the Company for the acquisition of FEMTOLASERS is allocated to the assets acquired, net of the liabilities assumed, based upon their estimated fair values as of the date of the acquisition. The excess of the purchase price over the estimated fair value of the assets acquired, net of the estimated fair value of the liabilities assumed, is recorded as goodwill. As discussed above, the Company has not yet finalized the purchase price. Any changes during the measurement period may have a further impact on goodwill.

Table of Contents

## NEWPORT CORPORATION

## Notes to Consolidated Financial Statements

October 3, 2015

|  | <b>October 3,<br/>2015<br/>Purchase<br/>Price<br/>Allocation</b> |
|--|--|
| Assets acquired and liabilities assumed: |  |
| Cash                                     | \$ 78  |
| Accounts receivable                      | 1,968  |
| Inventories                              | 2,759  |
| Deferred tax assets                      | 1,019  |
| Other assets                             | 2,015  |
| Goodwill                                 | 6,681  |
| Developed technology                     | 1,811  |
| In-process research and development      | 1,721  |
| Other intangible assets                  | 543  |
| Accounts payable                         | (3,417)  |
| Debt                                     | (4,021)  |
| Deferred tax liabilities                 | (1,019)  |
| Other liabilities                        | (2,195)  |
|  | \$ 7,943   |

The goodwill related to the acquisition of FEMTOLASERS has been allocated to the Company's Lasers Group and will not be deductible for tax purposes.

The actual net sales and net income (loss) of FEMTOLASERS from February 11, 2015, the closing date of the acquisition, were included in the Company's consolidated statements of income and comprehensive income for the three and nine months ended October 3, 2015, and are set forth in the table below. Also set forth in the table below are the pro forma net sales and net income of the Company during the three and nine months ended October 3, 2015 and September 27, 2014, including the results of FEMTOLASERS as though the acquisition had occurred at the beginning of 2014. This supplemental pro forma financial information is presented for information purposes only and is not necessarily indicative of the results of operations that would have been achieved if the acquisition had occurred as of the beginning of 2014.

| (Unaudited, in thousands)                             | Three Months Ended |                       | Nine Months Ended  |                       |
|---|--------------------|-----------------------|--------------------|-----------------------|
|   | October 3,<br>2015 | September 27,<br>2014 | October 3,<br>2015 | September 27,<br>2014 |
| Actual:   |                    |                       |                    |                       |
| Net sales   | \$ 2,166           | \$                    | \$ 4,489           | \$                    |
| Net income (loss) attributable to Newport Corporation | \$ 339             | \$                    | \$ (1,480)         | \$                    |
| Supplemental pro forma information:                   |                    |                       |                    |                       |
| Net sales   | \$ 147,560         | \$ 148,057            | \$ 452,461         | \$ 453,786            |
| Net income attributable to Newport Corporation        | \$ 7,121           | \$ 9,025              | \$ 21,926          | \$ 25,624             |
| Net income per share                                  |                    |                       |                    |                       |

Edgar Filing: NEWPORT CORP - Form 10-Q

|         |    |      |    |      |    |      |    |      |
|---------|----|------|----|------|----|------|----|------|
| Basic   | \$ | 0.18 | \$ | 0.23 | \$ | 0.56 | \$ | 0.64 |
| Diluted | \$ | 0.18 | \$ | 0.22 | \$ | 0.55 | \$ | 0.63 |

For the purposes of determining pro forma net income, adjustments were made to actual net income of the Company for all periods presented in the table above. The pro forma net income assumes that amortization of acquired intangible assets began at the beginning of 2014 rather than on February 11, 2015. The result is a net increase in amortization expense of \$0.1 million and \$0.4 million for the three and nine months ended September 27, 2014, respectively. Transaction costs totaling \$0.4 million, which were incurred prior to the closing of the acquisition, are excluded from pro forma net income.

Table of Contents

## NEWPORT CORPORATION

## Notes to Consolidated Financial Statements

October 3, 2015

## NOTE 4 FAIR VALUE MEASUREMENTS

Accounting Standards Codification (ASC) 820-10, *Fair Value Measurements*, requires the fair value of any assets and liabilities stated at fair value on a recurring basis in the Company's financial statements to be measured based on the price that would be received from selling such an asset or paid to transfer such a liability in an orderly transaction between market participants at the measurement date. Level 1 asset and liability values are derived from quoted prices in active markets for identical assets and liabilities, and Level 2 asset and liability values are derived from quoted prices in inactive markets or based on other observable inputs.

The Company's assets and liabilities measured at fair value on a recurring basis are categorized in the table below based upon their level within the fair value hierarchy as of October 3, 2015.

| (In thousands)<br>Description          | Fair Value Measurements at Reporting Date Using |   |   |  |
|--|---|---|---|--|
|  | October 3, 2015                                 | Quoted Prices in<br>Active Markets for<br>Identical Assets<br>(Level 1) | Significant Other<br>Observable Inputs<br>(Level 2) | Significant<br>Unobservable<br>Inputs<br>(Level 3) |
| Assets:                                |   |   |   |  |
| Restricted Cash                        | \$ 974  | \$ 974  | \$  | \$   |
| Derivative assets:                     |   |   |   |  |
| Option contracts                       | 214   |   | 214   |  |
| Funds in investments and other assets: |   |   |   |  |
| Israeli pension funds                  | 11,926  |   | 11,926  |  |
| Group insurance contracts              | 5,909   |   | 5,909   |  |
|  | 17,835  |   | 17,835  |  |
|  | \$ 19,023                                       | \$ 974  | \$ 18,049   | \$   |
| Liabilities:                           |   |   |   |  |
| Derivative liabilities:                |   |   |   |  |
| Option contracts                       | 266   |   | 266   |  |

Table of Contents

## NEWPORT CORPORATION

## Notes to Consolidated Financial Statements

October 3, 2015

The Company's assets and liabilities measured at fair value on a recurring basis are categorized in the table below based upon their level within the fair value hierarchy as of January 3, 2015.

| (In thousands)<br>Description             | January 3, 2015 | Fair Value Measurements at Reporting Date Using                         |   |  |
|---|-----------------|---|---|--|
|   |                 | Quoted Prices in<br>Active Markets for<br>Identical Assets<br>(Level 1) | Significant Other<br>Observable Inputs<br>(Level 2) | Significant<br>Unobservable<br>Inputs<br>(Level 3) |
| Assets:                                   |                 |   |   |  |
| Restricted Cash                           | \$ 1,704        | \$ 1,704  | \$  | \$   |
| Marketable securities:                    |                 |   |   |  |
| Money market funds                        | 7               | 7   |   |  |
| Certificates of deposit                   | 50              |   | 50  |  |
|   | 57              | 7   | 50  |  |
| Derivative assets:                        |                 |   |   |  |
| Option contracts                          | 103             |   | 103   |  |
| Funds in investments and other<br>assets: |                 |   |   |  |
| Israeli pension funds                     | 11,090          |   | 11,090  |  |
| Group insurance contracts                 | 6,140           |   | 6,140   |  |
|   | 17,230          |   | 17,230  |  |
|   | \$ 19,094       | \$ 1,711  | \$ 17,383   | \$   |
| Liabilities:                              |                 |   |   |  |
| Derivative liabilities:                   |                 |   |   |  |
| Option contracts                          | \$ 921          | \$  | \$ 921  | \$   |

The Company's other financial instruments include short-term borrowings and long-term debt. The fair value of these financial instruments was estimated based on current rates for similar issues or on the current rates offered to the Company for debt of similar remaining maturities. The estimated fair values of these financial instruments were as follows:

| (In thousands)        | October 3, 2015    |            | January 3, 2015    |            |
|-----------------------|--------------------|------------|--------------------|------------|
|                       | Carrying<br>Amount | Fair Value | Carrying<br>Amount | Fair Value |
| Short-term borrowings | \$ 3,579           | \$ 3,579   | \$ 3,772           | \$ 3,772   |
| Long-term debt        | \$ 84,254          | \$ 83,497  | \$ 71,000          | \$ 69,761  |

## NOTE 5

## SUPPLEMENTAL FINANCIAL INFORMATION



*Inventories*

Inventories that are expected to be sold within one year are classified as current inventories and are included in *inventories* in the accompanying consolidated balance sheets. Such inventories were as follows:

| <b>(In thousands)</b>             | <b>October 3,<br/>2015</b> | <b>January 3,<br/>2015</b> |
|-----------------------------------|----------------------------|----------------------------|
| Raw materials and purchased parts | \$ 75,111                  | \$ 68,989                  |
| Work in process                   | 18,747                     | 16,564                     |
| Finished goods                    | 28,987                     | 26,887                     |
| Short-term inventories            | \$ 122,845                 | \$ 112,440                 |

Table of Contents

## NEWPORT CORPORATION

## Notes to Consolidated Financial Statements

October 3, 2015

Inventories that are not expected to be sold within one year are classified as long-term inventories and are included in *investments and other assets* in the accompanying consolidated balance sheets. Such inventories were as follows:

| (In thousands)                    | October 3,<br>2015 | January 3,<br>2015 |
|-----------------------------------|--------------------|--------------------|
| Raw materials and purchased parts | \$ 2,138           | \$ 3,208           |
| Finished goods                    | 2,969              | 3,856              |
| Long-term inventories             | \$ 5,107           | \$ 7,064           |

*Accrued Warranty Obligations*

Unless otherwise stated in the Company's product literature or in its agreements with customers, products sold by the Company's Photonics and Optics Groups generally carry a one-year warranty from the original invoice date on all product materials and workmanship, other than filters and gratings products, which generally carry a 90-day warranty, and laser beam profilers and dental CAD/CAM scanners, which generally carry a two-year warranty. Products sold by the Photonics and Optics Groups to original equipment manufacturer (OEM) customers carry warranties generally ranging from 15 to 19 months. Products sold by the Company's Lasers Group carry warranties that vary by product and product component, but generally range from 90 days to two years. In certain cases, such warranties for Lasers Group products are limited by either a set time period or a maximum amount of hourly usage of the product, whichever occurs first. Defective products will be either repaired or replaced, generally at the Company's option, upon meeting certain criteria. The Company accrues a provision for the estimated costs that may be incurred for warranties relating to a product (based on historical experience) as a component of cost of sales. Short-term accrued warranty obligations, which expire within one year, are included in *accrued expenses and other current liabilities* and long-term warranty obligations are included in *other long-term liabilities* in the accompanying consolidated balance sheets.

The activity in accrued warranty obligations was as follows:

| (In thousands)                     | Nine Months Ended  |                       |
|------------------------------------|--------------------|-----------------------|
|                                    | October 3,<br>2015 | September 27,<br>2014 |
| Balance at beginning of year       | \$ 3,556           | \$ 3,285              |
| Additions charged to cost of sales | 2,278              | 2,134                 |
| Warranty claims                    | (2,386)            | (2,487)               |
| Balance at end of period           | \$ 3,448           | \$ 2,932              |

Table of Contents

## NEWPORT CORPORATION

## Notes to Consolidated Financial Statements

October 3, 2015

*Accrued Expenses and Other Current Liabilities*

Accrued expenses and other current liabilities were as follows:

| (In thousands)                          | October 3,<br>2015 | January 3,<br>2015 |
|---|--------------------|--------------------|
| Deferred revenue                        | \$ 12,246          | \$ 13,032          |
| Deferred lease liability                | 4,743              | 5,094              |
| Short-term accrued warranty obligations | 3,254              | 3,324              |
| Accrued third party commissions         | 1,551              | 1,395              |
| Accrued income taxes                    | 1,445              | 2,219              |
| Other                                   | 7,546              | 6,733              |
|   | \$ 30,785          | \$ 31,797          |

*Accumulated Other Comprehensive Loss*

Accumulated other comprehensive loss consisted of the following:

| (In thousands)  | October 3,<br>2015 | January 3,<br>2015 |
|---|--------------------|--------------------|
| Cumulative foreign currency translation losses                        | \$ (19,846)        | \$ (14,556)        |
| Unrecognized net pension losses, net of tax                           | (4,347)            | (4,855)            |
| Unrealized gains on investments and marketable securities, net of tax | 1,307              | 1,429              |
|   | \$ (22,886)        | \$ (17,982)        |

**NOTE 6 GOODWILL AND INTANGIBLE ASSETS**

The changes in the carrying amounts of goodwill were as follows:

| (In thousands) | Photonics<br>Group | Lasers<br>Group | Optics<br>Group | Total |
|----------------|--------------------|-----------------|-----------------|-------|
|----------------|--------------------|-----------------|-----------------|-------|

Edgar Filing: NEWPORT CORP - Form 10-Q

|                                   |           |           |           |            |
|-----------------------------------|-----------|-----------|-----------|------------|
| Balance at January 3, 2015:       |           |           |           |            |
| Goodwill                          | 98,808    | 129,761   | 41,314    | 269,883    |
| Accumulated impairment losses     | (47,458)  | (104,562) | (20,339)  | (172,359)  |
|                                   | 51,350    | 25,199    | 20,975    | 97,524     |
| Goodwill allocated to acquisition |           | 6,681     |           | 6,681      |
| Foreign currency impact           |           | (351)     |           | (351)      |
|                                   | 51,350    | 31,529    | 20,975    | 103,854    |
| Balance at October 3, 2015:       |           |           |           |            |
| Goodwill                          | 98,808    | 136,091   | 41,314    | 276,213    |
| Accumulated impairment losses     | (47,458)  | (104,562) | (20,339)  | (172,359)  |
|                                   | \$ 51,350 | \$ 31,529 | \$ 20,975 | \$ 103,854 |

Table of Contents

## NEWPORT CORPORATION

## Notes to Consolidated Financial Statements

October 3, 2015

As of October 3, 2015, acquisition related intangible assets were as follows:

| (In thousands)                                 | Amortization Period | Gross Value | Accumulated Amortization | Carrying Value |
|--|---------------------|-------------|--------------------------|----------------|
| Intangible assets subject to amortization:     |                     |             |                          |                |
| Developed technology                           | 10-20 years         | \$ 39,888   | \$ (11,777)              | \$ 28,111      |
| Customer relationships                         | up to 10 years      | 28,693      | (20,839)                 | 7,854          |
| In-process research and development            | 10 years            | 15,154      | (2,075)                  | 13,079         |
| Other  | 3 months-10 years   | 2,211       | (1,332)                  | 879            |
|  |                     | 85,946      | (36,023)                 | 49,923         |
| Intangible assets not subject to amortization: |                     |             |                          |                |
| Trademarks and trade names                     |                     | 18,305      |                          | 18,305         |
| Intangible assets                              |                     | \$ 104,251  | \$ (36,023)              | \$ 68,228      |

As of October 3, 2015, the gross values and accumulated amortization shown in the table above for intangible assets subject to amortization exclude amounts related to the Company's acquisition of Spectra-Physics, Inc. (and certain related entities), as the purchased intangible assets related to that acquisition have been fully amortized.

As of January 3, 2015, acquisition related intangible assets were as follows:

| (In thousands)                                 | Amortization Period | Gross Value | Accumulated Amortization | Carrying Value |
|--|---------------------|-------------|--------------------------|----------------|
| Intangible assets subject to amortization:     |                     |             |                          |                |
| Developed technology                           | 10-20 years         | \$ 45,646   | \$ (16,782)              | \$ 28,864      |
| Customer relationships                         | up to 10 years      | 47,827      | (37,312)                 | 10,515         |
| In-process research and development            | 10 years            | 13,461      | (1,496)                  | 11,965         |
| Other  | 3 months-10 years   | 7,461       | (6,299)                  | 1,162          |
|  |                     | 114,395     | (61,889)                 | 52,506         |
| Intangible assets not subject to amortization: |                     |             |                          |                |
| Trademarks and trade names                     |                     | 18,305      |                          | 18,305         |
| Intangible assets                              |                     | \$ 132,700  | \$ (61,889)              | \$ 70,811      |

Amortization expense related to intangible assets totaled \$2.1 million and \$1.9 million for the three months ended October 3, 2015 and September 27, 2014, respectively, and \$6.3 million and \$6.8 million for the nine months ended October 3, 2015 and September 27, 2014, respectively.

## Edgar Filing: NEWPORT CORP - Form 10-Q

Estimated aggregate amortization expense for future fiscal years is as follows:

| <b>(In thousands)</b> |    | <b>Estimated<br/>Aggregate<br/>Amortization<br/>Expense</b> |
|-----------------------|----|---|
| 2015 (remaining)      | \$ | 2,168   |
| 2016                  |    | 8,283   |
| 2017                  |    | 7,131   |
| 2018                  |    | 4,966   |
| 2019                  |    | 4,376   |
| Thereafter            |    | 20,015  |
|                       | \$ | 46,939  |

The Company has excluded \$3.0 million of estimated amortization expense related to certain in-process research and development from the table above, as it was uncertain as of October 3, 2015 when the technology will be completed and when the amortization will begin.

Table of Contents

## NEWPORT CORPORATION

## Notes to Consolidated Financial Statements

October 3, 2015

**NOTE 7 INTEREST AND OTHER EXPENSE, NET**

Interest and other expense, net, was as follows:

| (In thousands)                           | Three Months Ended |                       | Nine Months Ended  |                       |
|--|--------------------|-----------------------|--------------------|-----------------------|
|  | October 3,<br>2015 | September 27,<br>2014 | October 3,<br>2015 | September 27,<br>2014 |
| Interest expense                         | \$ (611)           | \$ (522)              | \$ (1,749)         | \$ (1,779)            |
| Interest and dividend income             | 18                 | 129                   | 86                 | 252                   |
| Derivative (loss) gain, net              | (430)              | (372)                 | 103                | (248)                 |
| Bank and portfolio asset management fees | (322)              | (293)                 | (1,015)            | (819)                 |
| Other (expense) income, net              | (8)                | 100                   | (745)              | 2                     |
|  | \$ (1,353)         | \$ (958)              | \$ (3,320)         | \$ (2,592)            |

**NOTE 8 STOCK-BASED COMPENSATION**

During the nine months ended October 3, 2015, the Company granted 0.5 million restricted stock units and 0.5 million stock-settled stock appreciation rights with weighted average grant date fair values of \$19.06 and \$7.60, respectively.

The total stock-based compensation expense included in the Company's consolidated statements of income and comprehensive income was as follows:

| (In thousands)                              | Three Months Ended |                       | Nine Months Ended  |                       |
|---|--------------------|-----------------------|--------------------|-----------------------|
|   | October 3,<br>2015 | September 27,<br>2014 | October 3,<br>2015 | September 27,<br>2014 |
| Cost of sales                               | \$ 367             | \$ 271                | \$ 1,048           | \$ 762                |
| Selling, general and administrative expense | 2,490              | 2,508                 | 7,812              | 6,809                 |
| Research and development expense            | 374                | 362                   | 1,198              | 1,017                 |
|   | \$ 3,231           | \$ 3,141              | \$ 10,058          | \$ 8,588              |

At October 3, 2015, the total compensation cost related to unvested stock-based awards granted to employees, officers and directors under the Company's stock-based benefit plans that had not yet been recognized was \$18.3 million, net of estimated forfeitures. This future compensation expense will be amortized over a weighted-average period of 1.9 years using the straight-line attribution method. The actual compensation

expense that the Company will recognize in the future related to unvested stock-based awards outstanding at October 3, 2015 will be adjusted for actual forfeitures and will be adjusted based on the Company's determination as to the extent to which performance conditions applicable to any stock-based awards have been or will be achieved.



Table of Contents

## NEWPORT CORPORATION

## Notes to Consolidated Financial Statements

October 3, 2015

At October 3, 2015, the Company's outstanding and exercisable stock options and stock appreciation rights, and the weighted average exercise price or base value, the weighted average remaining contractual life and the aggregate intrinsic value thereof, were as follows:

|   | Number of<br>Shares<br>(In thousands) | Weighted<br>Average<br>Exercise<br>Price or<br>Base<br>Value | Weighted<br>Average<br>Remaining<br>Contractual<br>Life (Years) | Aggregate<br>Intrinsic<br>Value<br>(In thousands) |
|---|---------------------------------------|--|---|---|
| Stock options outstanding and exercisable | 30                                    | \$ 13.86   | 0.3   | \$  |
| Stock appreciation rights outstanding     | 2,354                                 | \$ 15.61   | 4.4   | \$ 2,197  |
| Stock appreciation rights exercisable     | 1,328                                 | \$ 13.88   | 3.2   | \$ 2,187  |

## NOTE 9 DEBT AND LINES OF CREDIT

Total short-term borrowings were as follows:

| (In thousands)                            | October 3,<br>2015 | January 3,<br>2015 |
|---|--------------------|--------------------|
| Japanese revolving lines of credit        | \$ 3,117           | \$ 3,163           |
| Japanese receivables financing facilities | 312                | 25                 |
| Israeli loans due October 2015            | 150                | 584                |
| Total short-term borrowings               | \$ 3,579           | \$ 3,772           |

Total long-term debt was as follows:

| (In thousands)                                   | October 3,<br>2015 | January 3,<br>2015 |
|--|--------------------|--------------------|
| U.S. revolving line of credit expiring July 2018 | \$ 84,000          | \$ 71,000          |
| Austrian loans due through March 2019            | 254                |                    |
|  | \$ 84,254          | \$ 71,000          |

Table of Contents

## NEWPORT CORPORATION

## Notes to Consolidated Financial Statements

October 3, 2015

**NOTE 10 NET INCOME PER SHARE**

The following table sets forth the computation of basic and diluted net income per share:

| (In thousands, except per share data)                         | Three Months Ended |                       | Nine Months Ended  |                       |
|---|--------------------|-----------------------|--------------------|-----------------------|
|   | October 3,<br>2015 | September 27,<br>2014 | October 3,<br>2015 | September 27,<br>2014 |
| Net income attributable to Newport Corporation                | \$ 7,103           | \$ 9,470              | \$ 21,537          | \$ 26,308             |
| Shares:   |                    |                       |                    |                       |
| Weighted average shares outstanding - basic                   | 38,982             | 39,921                | 39,434             | 39,776                |
| Dilutive potential common shares, using treasury stock method | 392                | 691                   | 632                | 770                   |
| Weighted average shares outstanding - diluted                 | 39,374             | 40,612                | 40,066             | 40,546                |
| Net income per share attributable to Newport Corporation:     |                    |                       |                    |                       |
| Basic   | \$ 0.18            | \$ 0.24               | \$ 0.55            | \$ 0.66               |
| Diluted   | \$ 0.18            | \$ 0.23               | \$ 0.54            | \$ 0.65               |

For the three and nine months ended October 3, 2015, 1.5 million stock appreciation rights, and for the three and nine months ended September 27, 2014, an aggregate of 0.7 million stock options and stock appreciation rights, were excluded from the computations of diluted net income per share, as their inclusion would have been antidilutive. For the three and nine months ended October 3, 2015, 0.5 million performance-based restricted stock units, and for the three and nine months ended September 27, 2014, 0.6 million performance-based restricted stock units, were excluded from the computations of diluted net income per share, as the performance criteria for their vesting had not been met as of the end of such periods.

**NOTE 11 INCOME TAXES**

Income tax expense for each of the three and nine months ended October 3, 2015 and September 27, 2014 consisted of a provision for federal, state and foreign taxes based on the annual estimated effective tax rate applicable to the Company, adjusted for items which are considered discrete to a particular period. The effective tax rates for the three and nine months ended October 3, 2015 were 22.0% and 30.2%, respectively, and the effective tax rates for the three and nine months ended September 27, 2014 were 19.7% and 27.0%, respectively.

The effective tax rates for the three and nine months ended October 3, 2015 were lower than the U.S. statutory rate of 35% due primarily to the benefit of income recorded in foreign jurisdictions that have tax rates that are lower than U.S. tax rates and an increased utilization of foreign tax credits that were previously unrecognized, necessitated by the completion and filing of the 2014 U.S. federal consolidated return during the third quarter, which was recorded as a discrete item. The effective tax rate for the three months ended October 3, 2015 was also favorably impacted by profitable results recorded in jurisdictions where the Company maintains a full valuation allowance. The effective tax rate for the nine months ended October 3, 2015 was unfavorably impacted by the passage of Japanese tax reform legislation on March 31, 2015, which lowered long-term corporate tax rates, necessitating a corresponding reduction of deferred tax assets applicable to the Company's Japanese locations. The effective tax rates for the three and nine months ended September 27, 2014 were lower than the rates for the three and nine months ended October 3, 2015, respectively, due primarily to the favorable impact of an extraterritorial income exclusion benefit and a reduction of the corresponding uncertain tax position, which was recorded as a discrete item during the third quarter of 2014.

**NOTE 12**

**STOCKHOLDERS' EQUITY TRANSACTIONS**

In May 2008, the Board of Directors of the Company approved a share repurchase program, authorizing the purchase of up to 4.0 million shares of the Company's common stock. During the nine months ended October 3, 2015, the Company repurchased 1.7 million shares for a total of \$27.9 million under this program. As of October 3, 2015, 1.7 million shares remained available for purchase under the program.

Table of Contents**NEWPORT CORPORATION****Notes to Consolidated Financial Statements****October 3, 2015**

During the nine months ended October 3, 2015, the Company cancelled 0.2 million shares of common stock underlying restricted stock units in payment by employees of taxes owed upon the vesting of restricted stock units issued to them under the Company's stock incentive plans. The value of these restricted stock units totaled \$3.4 million at the time they were cancelled.

**NOTE 13      DEFINED BENEFIT PENSION PLANS**

The Company has defined benefit pension plans covering substantially all full-time employees in France, Germany, Israel and Japan. In addition, the Company has certain pension liabilities relating to former employees of the Company in the United Kingdom. The Company's German plan is unfunded, as permitted under the plan and applicable laws. For financial reporting purposes, the calculation of net periodic pension costs is based upon a number of actuarial assumptions, including a discount rate for plan obligations, an assumed rate of return on pension plan assets and an assumed rate of compensation increase for employees covered by the plan. All of these assumptions are based upon management's judgment, considering all known trends and uncertainties. Actual results that differ from these assumptions would impact future expense recognition and the cash funding requirements of the Company's pension plans.

Net periodic benefit costs for the plans in aggregate included the following components:

| (In thousands)                       | Three Months Ended |                       | Nine Months Ended  |                       |
|--------------------------------------|--------------------|-----------------------|--------------------|-----------------------|
|                                      | October 3,<br>2015 | September 27,<br>2014 | October 3,<br>2015 | September 27,<br>2014 |
| Service cost                         | \$ 547             | \$ 482                | \$ 1,849           | \$ 1,740              |
| Interest cost on benefit obligations | 120                | 198                   | 362                | 514                   |
| Expected return on plan assets       | (44)               | (70)                  | (131)              | (211)                 |
| Amortization of net loss             | 91                 | 44                    | 273                | 134                   |
|                                      | \$ 714             | \$ 654                | \$ 2,353           | \$ 2,177              |

**NOTE 14      BUSINESS SEGMENT INFORMATION**

The operating segments reported below are the segments of the Company for which separate financial information is available and for which operating results are evaluated regularly by the Chief Executive Officer, who is the chief operating decision maker, in deciding how to allocate resources and in assessing performance. The Company develops, manufactures and markets its products within three distinct business segments: its Photonics Group, its Lasers Group and its Optics Group.



Table of Contents**NEWPORT CORPORATION****Notes to Consolidated Financial Statements****October 3, 2015**

The Company measured income reported for each operating segment, which included only those costs that were directly attributable to the operations of that segment, and excluded unallocated operating expenses, such as corporate overhead and intangible asset amortization, certain gains and losses, interest and other expense, net, and income taxes.

| <b>(In thousands)</b>                         | <b>Photonics</b> | <b>Lasers</b> | <b>Optics</b> | <b>Total</b> |
|---|------------------|---------------|---------------|--------------|
| <b>Three months ended October 3, 2015:</b>    |                  |               |               |              |
| Sales to external customers                   | \$ 60,904        | \$ 48,247     | \$ 38,409     | \$ 147,560   |
| Segment income                                | \$ 14,274        | \$ 4,278      | \$ 3,168      | \$ 21,720    |
| <b>Three months ended September 27, 2014:</b> |                  |               |               |              |
| Sales to external customers                   | \$ 59,757        | \$ 44,228     | \$ 42,314     | \$ 146,299   |
| Segment income                                | \$ 12,255        | \$ 6,423      | \$ 4,949      | \$ 23,627    |
| <b>Nine months ended October 3, 2015:</b>     |                  |               |               |              |
| Sales to external customers                   | \$ 186,843       | \$ 142,602    | \$ 122,747    | \$ 452,192   |
| Segment income                                | \$ 46,703        | \$ 10,943     | \$ 12,803     | \$ 70,449    |
| <b>Nine months ended September 27, 2014:</b>  |                  |               |               |              |
| Sales to external customers                   | \$ 182,693       | \$ 137,815    | \$ 125,913    | \$ 446,421   |
| Segment income                                | \$ 40,201        | \$ 18,151     | \$ 14,494     | \$ 72,846    |

The following table reconciles segment income to consolidated income before income taxes:

| <b>(In thousands)</b>             | <b>Three Months Ended</b>  |                               | <b>Nine Months Ended</b>   |                               |
|-----------------------------------|----------------------------|-------------------------------|----------------------------|-------------------------------|
|                                   | <b>October 3,<br/>2015</b> | <b>September 27,<br/>2014</b> | <b>October 3,<br/>2015</b> | <b>September 27,<br/>2014</b> |
| Segment income                    | \$ 21,720                  | \$ 23,627                     | \$ 70,449                  | \$ 72,846                     |
| Unallocated operating expenses    | (11,255)                   | (10,866)                      | (35,196)                   | (34,485)                      |
| (Loss) gain on disposal of assets |                            |                               | (1,088)                    | 411                           |
| Interest and other expense, net   | (1,353)                    | (958)                         | (3,320)                    | (2,592)                       |
|                                   | \$ 9,112                   | \$ 11,803                     | \$ 30,845                  | \$ 36,180                     |

Table of Contents

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

*This Management's Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with our unaudited consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q and in conjunction with our Annual Report on Form 10-K for the year ended January 3, 2015 previously filed with the SEC. This discussion contains descriptions of our expectations regarding future trends affecting our business. Words such as anticipate, believe, can, continue, could, estimate, expect, intend, may, plan, potential, predict, should, will, would, or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. In addition, any statements that refer to projections of our future financial performance or condition, trends in our business, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements and other forward-looking statements made elsewhere in this report are made in reliance upon safe harbor provisions in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of several factors, including, but not limited to those factors set forth and discussed in Item 1 (Business) and Item 1A (Risk Factors) of Part I, and Item 7 (Management's Discussion and Analysis of Financial Condition and Results of Operations) of Part II, of our Annual Report on Form 10-K for the year ended January 3, 2015. In light of the significant uncertainties inherent in the forward-looking information included in this report, the inclusion of this information should not be regarded as a representation by us or any other person that our objectives or plans will be achieved and readers are cautioned not to place undue reliance on such forward-looking information. Except as required by law, we undertake no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.*

**Overview**

We are a global supplier of advanced-technology products and systems, including lasers, photonics instrumentation, precision positioning and vibration isolation products and systems, optical components, subassemblies and subsystems, and three-dimensional non-contact measurement equipment. Our products are used worldwide in a variety of industries, including scientific research, defense and security, microelectronics, life and health sciences and industrial markets. We operate within three distinct business segments: our Photonics Group, our Lasers Group and our Optics Group. Each of these groups offers a broad array of advanced technology products and services to original equipment manufacturer (OEM) and end-user customers across a wide range of applications in all of our targeted end markets.

The following is a discussion and analysis of certain factors that have affected our results of operations and financial condition during the periods included in the accompanying unaudited consolidated financial statements.

**Acquisition of FEMTOLASERS**

On February 11, 2015, we acquired all of the capital stock of FEMTOLASERS Produktions GmbH (FEMTOLASERS). The initial purchase price of 9.1 million was paid in cash at closing and is subject to a net asset adjustment. We have estimated a net asset adjustment of 2.1 million,

## Edgar Filing: NEWPORT CORP - Form 10-Q

resulting in a purchase price of 7.0 million (approximately \$7.9 million). The final amount of this net asset adjustment is currently under negotiation between us and the FEMTOLASERS selling shareholders. Of the initial purchase price, 2.3 million was deposited at closing into escrow until 30 months after closing, to secure certain obligations of the FEMTOLASERS selling shareholders under the share purchase agreement, including the net asset adjustment. We incurred \$0.4 million in transaction costs, which have been expensed as incurred and are included in *selling, general and administrative expense* in the statements of income and comprehensive income. FEMTOLASERS expands our offering of ultrafast laser products and enhances our technology base in this area. The results of FEMTOLASERS have been included in the results of our Lasers Group as of the acquisition date.

Immediately following the closing of the acquisition, we repaid 3.6 million (approximately \$4.0 million) of FEMTOLASERS outstanding loans that were assumed as part of the acquisition.



Table of Contents**Results of Operations for the Three and Nine Months Ended October 3, 2015 and September 27, 2014**

The following table presents our results of operations for the periods indicated as a percentage of net sales:

|  | Percentage of Net Sales |                       |                    |                       |
|--|-------------------------|-----------------------|--------------------|-----------------------|
|  | Three Months Ended      |                       | Nine Months Ended  |                       |
|  | October 3,<br>2015      | September 27,<br>2014 | October 3,<br>2015 | September 27,<br>2014 |
| Net sales  | 100.0%                  | 100.0%                | 100.0%             | 100.0%                |
| Cost of sales  | 57.7                    | 54.9                  | 56.5               | 54.9                  |
| Gross profit   | 42.3                    | 45.1                  | 43.5               | 45.1                  |
| Selling, general and administrative expense          | 25.6                    | 26.8                  | 25.9               | 27.0                  |
| Research and development expense                     | 9.6                     | 9.6                   | 9.8                | 9.5                   |
| Loss (gain) on sale of assets                        |                         |                       | 0.2                | (0.1)                 |
| Operating income                                     | 7.1                     | 8.7                   | 7.6                | 8.7                   |
| Interest and other expense, net                      | (0.9)                   | (0.6)                 | (0.7)              | (0.6)                 |
| Income before income taxes                           | 6.2                     | 8.1                   | 6.9                | 8.1                   |
| Income tax provision                                 | 1.4                     | 1.6                   | 2.1                | 2.2                   |
| Net income   | 4.8                     | 6.5                   | 4.8                | 5.9                   |
| Net income attributable to non-controlling interests |                         | 0.0                   |                    | 0.0                   |
| Net income attributable to Newport Corporation       | 4.8%                    | 6.5%                  | 4.8%               | 5.9%                  |

**Net Sales**

Each of our operating groups sells products to customers in a wide range of industries, which we categorize into five key end markets: scientific research market; defense and security markets; microelectronics market; life and health sciences market; and industrial manufacturing and other end markets. The tables below reflect our net sales for the three and nine months ended October 3, 2015 and September 27, 2014, by operating group and by key end market.

**Sales by Operating Group**

| (In thousands)  | Three Months Ended |                       |          | Increase /<br>(Decrease) | Percentage<br>Increase /<br>(Decrease) |
|-----------------|--------------------|-----------------------|----------|--------------------------|--|
|                 | October 3,<br>2015 | September 27,<br>2014 |          |                          |  |
| Photonics Group | \$ 60,904          | \$ 59,757             | \$ 1,147 | 1.9%                     |  |
| Lasers Group    | 48,247             | 44,228                | 4,019    | 9.1                      |  |
| Optics Group    | 38,409             | 42,314                | (3,905)  | (9.2)                    |  |
| Total sales     | \$ 147,560         | \$ 146,299            | \$ 1,261 | 0.9%                     |  |

Edgar Filing: NEWPORT CORP - Form 10-Q

| (In thousands)  | Nine Months Ended  |                       | Increase /<br>(Decrease) | Percentage<br>Increase /<br>(Decrease) |
|-----------------|--------------------|-----------------------|--------------------------|--|
|                 | October 3,<br>2015 | September 27,<br>2014 |                          |  |
| Photonics Group | \$ 186,843         | \$ 182,693            | \$ 4,150                 | 2.3%                                   |
| Lasers Group    | 142,602            | 137,815               | 4,787                    | 3.5                                    |
| Optics Group    | 122,747            | 125,913               | (3,166)                  | (2.5)                                  |
| Total sales     | \$ 452,192         | \$ 446,421            | \$ 5,771                 | 1.3%                                   |

Table of Contents*Sales by End Market*

| (In thousands)                     | Three Months Ended |                       | Increase /<br>(Decrease) | Percentage<br>Increase /<br>(Decrease) |
|------------------------------------|--------------------|-----------------------|--------------------------|--|
|                                    | October 3,<br>2015 | September 27,<br>2014 |                          |  |
| Scientific research                | \$ 36,414          | \$ 32,228             | \$ 4,186                 | 13.0%                                  |
| Microelectronics                   | 34,945             | 37,113                | (2,168)                  | (5.8)                                  |
| Life and health sciences           | 29,354             | 31,126                | (1,772)                  | (5.7)                                  |
| Defense and security               | 14,770             | 13,103                | 1,667                    | 12.7                                   |
| Industrial manufacturing and other | 32,077             | 32,729                | (652)                    | (2.0)                                  |
| Total sales                        | \$ 147,560         | \$ 146,299            | \$ 1,261                 | 0.9%                                   |

| (In thousands)                     | Nine Months Ended  |                       | Increase /<br>(Decrease) | Percentage<br>Increase /<br>(Decrease) |
|------------------------------------|--------------------|-----------------------|--------------------------|--|
|                                    | October 3,<br>2015 | September 27,<br>2014 |                          |  |
| Scientific research                | \$ 105,200         | \$ 94,653             | \$ 10,547                | 11.1%                                  |
| Microelectronics                   | 113,770            | 111,935               | 1,835                    | 1.6                                    |
| Life and health sciences           | 88,281             | 97,781                | (9,500)                  | (9.7)                                  |
| Defense and security               | 44,241             | 39,161                | 5,080                    | 13.0                                   |
| Industrial manufacturing and other | 100,700            | 102,891               | (2,191)                  | (2.1)                                  |
| Total sales                        | \$ 452,192         | \$ 446,421            | \$ 5,771                 | 1.3%                                   |

Our sales for the three and nine months ended October 3, 2015 were negatively impacted by the stronger U.S. dollar, which resulted in the translation of foreign currency denominated sales into fewer U.S. dollars, compared with the corresponding periods in 2014. Our sales for both periods in 2015 were positively impacted compared with the corresponding periods in 2014 by the additional sales contributed by V-Gen Ltd. (V-Gen), which we acquired in the fourth quarter of 2014, and by FEMTOLASERS, which we acquired in the first quarter of 2015. The aggregate sales of these acquired businesses, which are included in our Lasers Group, were \$3.6 million and \$10.7 million for the three and nine months ended October 3, 2015, respectively, and there were no corresponding sales in the three and nine months ended September 27, 2014.

The increases in sales to the scientific research market for the three and nine months ended October 3, 2015 compared with the corresponding periods in 2014 were due primarily to increased demand for products sold by our Lasers Group for research applications, and our acquisition of FEMTOLASERS, which contributed net sales to this market of \$2.2 million and \$4.5 million for the three and nine months ended October 3, 2015, respectively, for which there were no corresponding sales in the 2014 periods. Generally, our net sales to this market by each of our operating groups may fluctuate from period to period due to changes in overall research spending levels and the timing of large sales relating to major research programs and, in some cases, these fluctuations may be offsetting between our operating groups or between such periods.

The decrease in sales to the microelectronics market for the three months ended October 3, 2015 compared with the corresponding period in 2014 was due primarily to lower sales by both our Lasers and Optics Groups to semiconductor equipment manufacturing customers, as well as a large sale of laser products for a solar equipment manufacturing application in the third quarter of 2014 that did not recur in the third quarter of 2015. Such decreases were offset in part by higher sales by our Photonics Group to semiconductor equipment manufacturing customers. The increase in sales to this market in the nine months ended October 3, 2015 compared with the corresponding period in 2014 was due primarily to higher sales by our Photonics Group to semiconductor equipment and mobile device manufacturing customers, offset in part by the lower sales by our Lasers and Optics Groups discussed above. Our microelectronics market is comprised primarily of OEM customers in the semiconductor capital equipment industry, which has historically been characterized by sudden and severe cyclical variations in product supply and demand. In addition, certain of our programs with these customers often comprise a significant portion of our sales to this market in any period. As such, our net sales to this market may fluctuate significantly from period to period depending on the timing and severity of industry upturns and downturns, as well as the timing and success of new design wins and associated customer programs.



Table of Contents

The decreases in sales to the life and health sciences market for the three and nine months ended October 3, 2015 compared with the corresponding periods in 2014 were due primarily to decreased sales of products used for surgical and dental imaging applications. For the three month period, the decrease was offset in part by increased sales of products used in bioimaging applications. Generally, our net sales to this market may fluctuate from period to period due to the timing of shipments to our OEM customers and, in some cases, these fluctuations may be offsetting between our operating groups or between such periods.

The increase in sales to the defense and security markets for the three months ended October 3, 2015 compared with the corresponding period in 2014 was due to moderately higher sales by each of our operating groups. The increase in sales to these markets for the nine months ended October 3, 2015 compared with the corresponding period in 2014 was due primarily to increased sales of optics products for defense programs that had been previously delayed due to government funding constraints and for new programs. Generally, our net sales to these markets by each of our operating groups may fluctuate from period to period due to changes in overall defense spending levels and the timing of large sales relating to major defense programs and, in some cases, these fluctuations may be offsetting between our operating groups or between such periods.

The decrease in sales to the industrial manufacturing and other end markets for the three months ended October 3, 2015 compared with the corresponding period in 2014 was due to general weakness in macro-economic conditions. The decrease in sales to these markets for the nine months ended October 3, 2015 compared with the corresponding period in 2014 was due primarily to lower sales of test systems for diode laser manufacturing applications, as well as general weakness in macro-economic conditions. These decreases were offset in part by our acquisition of V-Gen, which contributed net sales to these markets of \$0.5 million and \$3.8 million for the three and nine months ended October 3, 2015, respectively, for which there were no corresponding sales in the 2014 periods.

The table below reflects our net sales by geographic region. Sales are attributed to each region based on the customer address to which the product is shipped.

| (In thousands)              | Three Months Ended |                       | Increase /<br>(Decrease) | Percentage<br>Increase /<br>(Decrease) |
|-----------------------------|--------------------|-----------------------|--------------------------|--|
|                             | October 3,<br>2015 | September 27,<br>2014 |                          |  |
| United States               | \$ 58,521          | \$ 58,556             | \$ (35)                  | (0.1)%                                 |
| Germany                     | 16,413             | 19,408                | (2,995)                  | (15.4)                                 |
| Other European countries    | 22,281             | 20,344                | 1,937                    | 9.5                                    |
| Japan                       | 12,646             | 10,754                | 1,892                    | 17.6                                   |
| Other Pacific Rim countries | 27,516             | 27,741                | (225)                    | (0.8)                                  |
| Rest of world               | 10,183             | 9,496                 | 687                      | 7.2                                    |
|                             | \$ 147,560         | \$ 146,299            | \$ 1,261                 | 0.9%                                   |

| (In thousands)              | Nine Months Ended  |                       | Increase /<br>(Decrease) | Percentage<br>Increase /<br>(Decrease) |
|-----------------------------|--------------------|-----------------------|--------------------------|--|
|                             | October 3,<br>2015 | September 27,<br>2014 |                          |  |
| United States               | \$ 177,748         | \$ 169,079            | \$ 8,669                 | 5.1%                                   |
| Germany                     | 49,924             | 60,702                | (10,778)                 | (17.8)                                 |
| Other European countries    | 67,122             | 63,278                | 3,844                    | 6.1                                    |
| Japan                       | 40,202             | 40,486                | (284)                    | (0.7)                                  |
| Other Pacific Rim countries | 85,056             | 81,217                | 3,839                    | 4.7                                    |
| Rest of world               | 32,140             | 31,659                | 481                      | 1.5                                    |
|                             | \$ 452,192         | \$ 446,421            | \$ 5,771                 | 1.3%                                   |

Edgar Filing: NEWPORT CORP - Form 10-Q

The increase in sales to customers in the United States for the nine months ended October 3, 2015 compared with the corresponding period in 2014 was due primarily to increased sales to customers in our scientific research and defense and security end markets.

Table of Contents

The decrease in sales to customers in Germany for the three months ended October 3, 2015 compared with the corresponding period in 2014 was due primarily to lower sales to customers in our life and health sciences and industrial manufacturing end markets, offset in part by higher sales to customers in our scientific research end market. The decrease in sales to customers in Germany for the nine months ended October 3, 2015 compared with the corresponding period in 2014 was due to lower sales to customers in all of our end markets.

The increases in sales to customers in other European countries for the three and nine months ended October 3, 2015 compared with the same periods in 2014 were due primarily to higher sales to customers in our scientific research end market. Such increases were offset in part by lower sales to customers in our industrial manufacturing and other end markets and, for the nine month period, such increases were also offset in part by lower sales to customers in our life and health sciences end market.

The increase in sales to customers in Japan for the three months ended October 3, 2015 compared with the corresponding period in 2014 was due primarily to increased sales to customers in our microelectronics end market, offset in part by lower sales to customers in our life and health sciences end market. The decrease in sales to customers in Japan for the nine months ended October 3, 2015 compared with the corresponding period in 2014 was due primarily to lower sales to customers in our life and health sciences and scientific research end markets, offset in part by higher sales to customers in our microelectronics end market.

The decrease in sales to customers in other Pacific Rim countries for the three months ended October 3, 2015 compared with the corresponding period in 2014 was due primarily to lower sales to customers in our microelectronics end market, offset in large part by increased sales to customers in our scientific research end market. The increase in sales to customers in other Pacific Rim countries for the nine months ended October 3, 2015 compared with the corresponding period in 2014 was due primarily to higher sales to customers in our scientific research end market, offset in part by lower sales to customers in our microelectronics and life and health sciences end markets.

The increases in sales to customers in the rest of the world for the three and nine months ended October 3, 2015 compared with the corresponding periods in 2014 were due primarily to higher sales to customers in our defense and security end markets, offset in part by lower sales to customers in our scientific research end market.

Our sales in the third quarter and first nine months of 2015 in certain geographic locations, particularly in Europe and Japan, were negatively impacted by the stronger U.S. dollar, which resulted in the translation of such sales into fewer U.S. dollars, compared with the corresponding periods in 2014.

***Gross Margin***

Gross margin was 42.3% and 45.1% for the three months ended October 3, 2015 and September 27, 2014, respectively, and gross margin was 43.5% and 45.1% for the nine months ended October 3, 2015 and September 27, 2014, respectively. The gross margin of our Lasers Group was negatively impacted for the three and nine months ended October 3, 2015 due to a higher proportion of sales of lower margin products, particularly products sold by recently acquired businesses, as we work to improve operational efficiencies and reduce costs as part of the integration of these businesses. In addition, gross margins were negatively impacted due to lower absorption of manufacturing overhead resulting from the lower production levels. For the nine month period, our Lasers Group's gross margin was also negatively impacted by increased inventory charges. The gross margin of our Optics Group was negatively impacted in both periods by lower absorption of

## Edgar Filing: NEWPORT CORP - Form 10-Q

manufacturing overhead at our North Andover facility, as we transition the operations of that facility to other facilities, and by increased inventory charges. Our gross margins in both periods in 2015 were also negatively impacted by the stronger U.S. dollar, which resulted in the translation of our foreign currency denominated sales into fewer U.S. dollars. This negative impact was offset in part by lower manufacturing costs in certain locations due to the stronger U.S. dollar.

In general, we expect that our gross margin will vary in any given period depending upon factors such as our mix of sales, product pricing variations, manufacturing absorption levels, and changes in levels of inventory and warranty reserves.



Table of Contents

***Selling, General and Administrative (SG&A) Expense***

SG&A expense totaled \$37.7 million, or 25.6% of net sales, and \$39.1 million, or 26.8% of net sales, for the three months ended October 3, 2015 and September 27, 2014, respectively. SG&A expense totaled \$117.0 million, or 25.9% of net sales, and \$120.4 million, or 27.0% of net sales, for the nine months ended October 3, 2015 and September 27, 2014, respectively. The decrease in SG&A expense for the three months ended October 3, 2015 compared with the corresponding period in 2014 was due primarily to lower depreciation expense and professional fees. The decrease in SG&A expense for the nine months ended October 3, 2015 compared with the corresponding period in 2014 was due primarily to lower incentive compensation and travel expenses, as well as lower depreciation expense and professional fees. The stronger U.S. dollar in certain locations also contributed to the decreases in SG&A expense for both periods in 2015. The decreases for both periods in 2015 were offset in part by higher rental costs and software licensing fees, and by the addition of SG&A expenses for V-Gen and FEMTOLASERS, for which there were no corresponding expenses in the prior year periods.

We have implemented certain cost reduction actions during 2015, which have resulted in lower personnel costs; however, for both periods in 2015, such decreases in personnel costs were offset in large part by increased severance costs related to such actions. We expect our SG&A expense to be more favorably impacted by our cost reduction actions in future periods once all actions have been completed.

In general, we expect that SG&A expense will vary as a percentage of net sales in the future based on our sales level in any given period. Because the majority of our SG&A expense is fixed in the short term, changes in SG&A expense will likely not be in proportion to changes in net sales. In addition, any acquisitions would increase our SG&A expense, and such increases may not be in proportion to the changes in net sales.

***Research and Development (R&D) Expense***

R&D expense totaled \$14.2 million, or 9.6% of net sales, and \$14.1 million, or 9.6% of net sales, for the three months ended October 3, 2015 and September 27, 2014, respectively. R&D expense totaled \$44.3 million, or 9.8% of net sales, and \$42.5 million, or 9.5% of net sales, for the nine months ended October 3, 2015 and September 27, 2014, respectively. The increases in R&D expense for the three and nine months ended October 3, 2015 compared with the corresponding periods in 2014 were due primarily to the addition of R&D expenses of V-Gen and FEMTOLASERS, for which there were no corresponding expenses in the prior year periods, offset in part by the impact of the stronger U.S. dollar in certain locations and the benefits of our cost reduction actions.

We believe that the continued development and advancement of our products and technologies is critical to our success, and we intend to continue to invest in R&D initiatives, while working to ensure that our efforts are focused and the resources are deployed efficiently. In general, we expect that R&D expense as a percentage of net sales will vary in the future based on our sales level in any given period. Because of our commitment to continued product development, and because the majority of our R&D expense is fixed in the short term, changes in R&D expense will likely not be in proportion to changes in net sales. In addition, any acquisitions would increase our R&D expense, and such increases may not be in proportion to the changes in net sales.

*Loss on Disposal of Assets*

During the first quarter of 2015, we entered into a plan to transfer the operations of our North Andover, Massachusetts facility to certain of our other facilities and to close that facility. In connection with this plan, we determined that the carrying value of leasehold improvements for this facility was not recoverable and recorded an impairment loss of \$1.1 million.

*Interest and Other Expense, Net*

Interest and other expense, net totaled \$1.4 million and \$1.0 million for the three months ended October 3, 2015 and September 27, 2014, respectively. Interest and other expense, net totaled \$3.3 million and \$2.6 million for the nine months ended October 3, 2015 and September 27, 2014, respectively. The increases in interest and other expense, net for the three and nine months ended October 3, 2015 compared with the same periods in 2014 were due primarily to foreign currency transaction losses.

Table of Contents

***Income Taxes***

Our effective tax rate was 22.0% and 19.7% for the three months ended October 3, 2015 and September 27, 2014, respectively, and 30.2% and 27.0% for the nine months ended October 3, 2015 and September 27, 2014, respectively. Our effective tax rates for the three and nine months ended October 3, 2015 were lower than the U.S. statutory rate of 35% due primarily to the benefit of income recorded in foreign jurisdictions that have tax rates that are lower than U.S. tax rates and an increased utilization of foreign tax credits that were previously unrecognized, necessitated by the filing of the 2014 U.S. federal consolidated tax return during the third quarter, which was recorded as a discrete item. The effective tax rate for the three months ended October 3, 2015 was also favorably impacted by profitable results recorded in jurisdictions where we maintain a full valuation allowance. The effective tax rate for the nine months ended October 3, 2015 was unfavorably impacted by the passage of Japanese tax reform legislation on March 31, 2015, which lowered long-term corporate tax rates, necessitating a corresponding reduction of deferred tax assets applicable to our Japanese locations. The effective tax rates for the three and nine months ended September 27, 2014 were lower than the rates for the three and nine months ended October 3, 2015 due primarily to the favorable impact of an extraterritorial income exclusion benefit and a reduction of the corresponding uncertain tax position, which was recorded as a discrete item during the third quarter of 2014.

**Liquidity and Capital Resources**

Our cash and cash equivalents and restricted cash balances decreased to a total of \$31.4 million as of October 3, 2015 from \$48.6 million as of January 3, 2015. This decrease was attributable primarily to cash used in connection with repurchases of our common stock, purchases of property and equipment and our acquisition of FEMTOLASERS, offset in part by net cash provided by our operating activities and net borrowings.

Net cash provided by our operating activities of \$28.4 million for the nine months ended October 3, 2015 was attributable primarily to cash provided by our results of operations, offset in part by an increase in gross inventory of \$16.0 million, an increase in accounts receivable of \$7.0 million due to the timing of collections, and decreases in accrued payroll and other expenses of \$3.5 million and accounts payable of \$3.1 million due to the timing of payments.

Net cash used in investing activities of \$25.9 million for the nine months ended October 3, 2015 was attributable primarily to purchases of property and equipment of \$15.5 million and cash used in connection with our acquisition of FEMTOLASERS of \$10.2 million, including amounts that are expected to be refunded pursuant to a net asset adjustment.

Net cash used in financing activities of \$18.6 million for the nine months ended October 3, 2015 was attributable to payments of \$27.9 million to repurchase our common stock and payments of \$3.4 million in connection with the cancellation of shares of common stock underlying restricted stock units for taxes owed by employees upon vesting of restricted stock units issued under our stock incentive plans. These cash payments were offset in part by net borrowings of \$8.8 million, an excess tax benefit of \$2.6 million related to employee stock plans, and proceeds of \$1.4 million received from the issuance of common stock under employee stock plans.

On July 18, 2013, we entered into a credit agreement with certain lenders (Credit Agreement). The Credit Agreement consists of a senior secured revolving credit facility of \$275 million with a term of five years (Credit Facility). The Credit Agreement also provides us with the

## Edgar Filing: NEWPORT CORP - Form 10-Q

option to increase the aggregate principal amount of loans in the form of additional revolving loans or a separate tranche of term loans, in an aggregate amount that does not exceed \$50 million, in each case subject to certain terms and conditions contained in the Credit Agreement. At October 3, 2015, the outstanding balance under the Credit Facility was \$84.0 million, with an effective interest rate of 1.75%.

Our obligations under the Credit Agreement are secured by a lien on substantially all of the assets of Newport Corporation and certain of our domestic subsidiaries, which are guarantors under the Credit Agreement, as well as by a pledge of certain shares of our foreign subsidiaries. Our ability to borrow funds under the Credit Facility is subject to certain conditions, including compliance with certain covenants and making certain representations and warranties. In particular, our borrowing capacity under the Credit Facility is limited by our Consolidated Adjusted

Table of Contents

EBITDA (as defined in the Credit Agreement) for the preceding four fiscal quarters. At October 3, 2015, based on our Consolidated Adjusted EBITDA, the \$84.0 million borrowed under the Credit Facility, additional indebtedness of \$3.8 million and outstanding letters of credit of \$4.9 million, we had approximately \$140.3 million available for additional borrowing under the Credit Facility.

At October 3, 2015, we also had (i) revolving lines of credit with Japanese banks; (ii) an agreement with a Japanese bank under which we sell trade notes receivable with recourse; (iii) a loan with an Israeli bank; and (iv) loans from the Austrian government, as follows:

| Description                                 | Principal Amount Outstanding (in millions) | Additional Amount Available for Borrowing (in millions) | Interest Rate(s) | Expiration Date(s)  |
|---|--|---|------------------|---------------------|
| Japanese lines of credit                    | \$ 3.1                                     | \$ 1.9  | 1.27% to 2.20%   | No expiration dates |
| Japanese agreements for sale of receivables | \$ 0.3                                     | \$ 1.4  | 1.20%            | No expiration dates |
| Israeli loan                                | \$ 0.2                                     | \$  | 2.97%            | October 2015        |
| Austrian loans                              | \$ 0.3                                     | \$  | 0.75% to 2.00%   | Through March 2019  |

In May 2008, our Board of Directors approved a share repurchase program, authorizing the purchase of up to 4.0 million shares of our common stock. The terms of the Credit Agreement permit us to purchase shares under the repurchase program, subject to certain conditions and limitations. During the nine months ended October 3, 2015, we repurchased 1.7 million shares for a total of \$27.9 million under this program. As of October 3, 2015, 1.7 million shares remained available for purchase under the program. The amount and timing of future repurchases will be dependent upon factors such as our share price level, our other capital requirements and the terms of our Credit Agreement.

During the remainder of 2015, we expect to use approximately \$5 million to \$7 million of cash for capital expenditures.

We expect that our current working capital position, together with our expected future cash flows from operations and the borrowing availability under our Credit Facility and other lines of credit, will be adequate to fund our operations in the ordinary course of business, anticipated capital expenditures, our debt payment requirements and other contractual obligations for at least the next twelve months. While a substantial portion of our cash and cash equivalents and restricted cash is held outside of the United States, we currently do not intend or anticipate a need to repatriate such funds, as we expect that the cash and cash equivalents and restricted cash held in the United States, together with our cash flows from U.S. operations and the borrowing capacity under our Credit Facility, will be sufficient to fund our U.S. operations and cash commitments for investing and financing activities, including debt repayment and capital expenditures for at least the next twelve months and thereafter for the foreseeable future. However, these expectations are based upon many assumptions and are subject to numerous risks, including those discussed in Item 1A (Risk Factors) of Part I of our Annual Report on Form 10-K for the year ended January 3, 2015. In addition, under current tax laws and regulations, if cash and cash equivalents and investments held outside of the United States, which relate to undistributed earnings of certain of our foreign subsidiaries and are considered to be indefinitely reinvested, were to be distributed to the United States in the form of dividends or otherwise, we would be subject to additional U.S. income taxes (subject to an adjustment for foreign tax credits) and foreign withholding taxes. The potential tax liability related to any repatriation would depend on the tax laws of the United States and the respective foreign jurisdictions and on the facts and circumstances that exist at the time such repatriation is made.

## Edgar Filing: NEWPORT CORP - Form 10-Q

Except for the aforementioned capital expenditures, we have no present agreements or commitments with respect to any material acquisitions of businesses, products, product rights or technologies or any other material capital expenditures. We will continue to evaluate acquisitions of and/or investments in products, technologies, capital equipment or improvements and companies that complement our business and may make such acquisitions and/or investments in the future. However, our Credit Agreement only permits us to make investments and acquisitions under certain circumstances, and restricts our ability to incur additional indebtedness, which limits to some extent our ability to make such acquisitions and investments.

Table of Contents

**Critical Accounting Policies and Estimates**

The preparation of our consolidated financial statements requires that we make estimates and assumptions that affect the reported amounts of assets and liabilities and related disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. We evaluate these estimates and assumptions on an ongoing basis. We base our estimates on our historical experience and on various other factors which we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the amounts of certain expenses that are not readily apparent from other sources. The accounting policies that involve the most significant judgments, assumptions and estimates used in the preparation of our financial statements are those related to revenue recognition, allowances for doubtful accounts, pension liabilities, inventory reserves, warranty obligations, asset impairment, income taxes and stock-based compensation. The judgments, assumptions and estimates used in these areas by their nature involve risks and uncertainties, and in the event that any of them prove to be inaccurate in any material respect, it could have a material effect on our reported amounts of assets and liabilities at the date of the financial statements and on the reported amounts of revenues and expenses during the reporting periods. A summary of these critical accounting policies is included in Item 7 (Management's Discussion and Analysis of Financial Condition and Results of Operations) of Part II of our Annual Report on Form 10-K for the fiscal year ended January 3, 2015. There have been no material changes to the critical accounting policies disclosed in such Annual Report on Form 10-K.

**Recent Accounting Pronouncements**

In September 2015, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2015-16, *Simplifying the Accounting for Measurement Period Adjustments*. ASU No. 2015-16 requires an acquirer in a business combination to recognize adjustments to the provisional amounts that are identified during the measurement period to be reported in the period in which the adjustment amounts are determined. In addition, the effect on earnings of changes in depreciation or amortization, or other income effects (if any) as a result of the change to the provisional amounts, calculated as if the accounting had been completed as of the acquisition date, must be recorded in the reporting period in which the adjustment amounts are determined. ASU No. 2015-16 will be effective for fiscal years and interim periods beginning after December 15, 2015, and is required to be applied prospectively. Early adoption is permitted for financial statements that have not been issued prior to the effective date of this update. The adoption of ASU No. 2015-16 is not expected to have a material impact on our financial position or results of operations.

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

The principal market risks (i.e., the risk of loss arising from adverse changes in market rates and prices) to which we are exposed are changes in foreign exchange rates, which may generate translation and transaction gains and losses, and changes in interest rates.

**Foreign Currency Risk**

Operating in international markets sometimes involves exposure to volatile movements in currency exchange rates. The economic impact of currency exchange rate movements on our operating results is complex because such changes are often linked to variability in real growth, inflation, interest rates, governmental actions and other factors. These changes, if material, may cause us to adjust our financing and operating strategies. Consequently, isolating the effect of changes in currency does not incorporate these other important economic factors.

We use foreign currency option and forward exchange contracts to mitigate the risks associated with certain foreign currency transactions entered into in the ordinary course of business, primarily foreign currency denominated receivables, payables and other expenses. These derivative instruments are used as an economic hedge. However, we have not elected hedge accounting treatment and therefore, all changes in value of these derivative instruments are reflected in *interest and other expense, net* in our consolidated statements of income and comprehensive income. We do not engage in currency speculation. All of our foreign currency option and forward exchange contracts are established to reduce the volatility of earnings, primarily related to Israeli shekel-based expenses. If the counterparties to these contracts (typically highly rated banks) do not fulfill their obligations to deliver the contracted currencies, we could be at risk for any currency related fluctuations.



Table of Contents

As currency exchange rates change, translation of the statements of income of international operations into U.S. dollars affects the year-over-year comparability of operating results, particularly in translating foreign currency denominated sales into U.S. dollars. However, because we have manufacturing facilities located globally, the impact of currency exchange rate fluctuations on our income is mitigated in part by the translation of foreign currency denominated expenses. We do not generally hedge translation risks because cash flows from international operations are generally reinvested locally. Changes in currency exchange rates that would have the largest impact on translating our future international operating results include changes to the exchange rates of the U.S. dollar to the euro and Japanese yen.

The following table provides information about our foreign currency derivative financial instruments outstanding as of October 3, 2015. The information is presented in U.S. dollars, as presented in our consolidated financial statements:

| (In thousands)                | October 3, 2015 |                      |
|-------------------------------|-----------------|----------------------|
|                               | Notional Amount | Average Strike Price |
| Foreign currency options      |                 |                      |
| Israeli Shekel - call options | \$ 21,352       | 4.03                 |
| Israeli Shekel - put options  | (22,822)        | 3.77                 |
|                               | \$ (1,470)      |                      |
| Fair value                    | \$ (52)         |                      |

**Interest Rate Risk**

Our investments in cash, cash equivalents and restricted cash, which totaled \$31.4 million at October 3, 2015, are sensitive to changes in the general level of interest rates. In addition, certain assets related to our pension plans are sensitive to interest rates and economic conditions in Europe and Asia.

We have a \$275 million revolving line of credit in the United States. We also have lines of credit and other loans in Israel, Austria and Japan. Our revolving line of credit in the United States and our other borrowings carry variable interest rates and therefore are subject to interest rate risk.

The table below presents information about our debt obligations as of October 3, 2015:

| (US\$ equivalent in thousands) | Expected Maturity Date |       |       |           |        |            |           | Fair Value |
|--------------------------------|------------------------|-------|-------|-----------|--------|------------|-----------|------------|
|                                | 2015                   | 2016  | 2017  | 2018      | 2019   | Thereafter | Total     |            |
| Debt obligations:              |                        |       |       |           |        |            |           |            |
| Fixed rate (US\$)              | \$ 150                 | \$    | \$ 90 | \$ 12     | \$ 152 | \$         | \$ 404    | \$ 399     |
| Weighted average interest rate | 2.97%                  | 0.00% | 2.00% | 2.00%     | 0.75%  | 0.00%      | 1.89%     |            |
| Variable rate (US\$)           | \$                     | \$    | \$    | \$ 84,000 | \$     | \$         | \$ 84,000 | \$ 83,248  |
| Weighted average interest rate | 0.00%                  | 0.00% | 0.00% | 1.75%     | 0.00%  | 0.00%      | 1.75%     |            |
| Variable rate (non-US\$)       | \$ 3,429               | \$    | \$    | \$        | \$     | \$         | \$ 3,429  | \$ 3,429   |
| Weighted average interest rate | 1.26%                  | 0.00% | 0.00% | 0.00%     | 0.00%  | 0.00%      | 1.26%     |            |
| Total debt obligations         | \$ 3,579               | \$    | \$ 90 | \$ 84,012 | \$ 152 | \$         | \$ 87,833 | \$ 87,076  |

Edgar Filing: NEWPORT CORP - Form 10-Q

|                                |       |       |       |       |       |       |       |
|--------------------------------|-------|-------|-------|-------|-------|-------|-------|
| Weighted average interest rate | 1.33% | 0.00% | 0.00% | 1.75% | 0.00% | 0.00% | 1.73% |
|--------------------------------|-------|-------|-------|-------|-------|-------|-------|

Table of Contents

**ITEM 4. CONTROLS AND PROCEDURES**

**(a) Evaluation of Disclosure Controls and Procedures**

Our Chief Executive Officer and our Chief Financial Officer, after evaluating our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the Exchange Act )) as of the end of the period covered by this Quarterly Report on Form 10-Q (the Evaluation Date ), have concluded that as of the Evaluation Date, our disclosure controls and procedures were effective to ensure that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms, and to ensure that information required to be disclosed by us in such reports is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer where appropriate, to allow timely decisions regarding required disclosure.

**(b) Changes in Internal Control Over Financial Reporting**

There was no change in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents**PART II. OTHER INFORMATION****ITEM 1A. RISK FACTORS**

Our Annual Report on Form 10-K for the year ended January 3, 2015 contains a full discussion of the risks associated with our business. There have been no material changes to the risks described in our Annual Report on Form 10-K.

**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

The following table reflects purchases made by us during the quarter ended October 3, 2015, of equity securities that are registered by us pursuant to Section 12 of the Securities Exchange Act of 1934, as amended:

| Period(1)                            | Total Number of<br>Shares (or Units)<br>Purchased | Average Price<br>Paid per Share<br>(or Unit) | Total Number of<br>Shares (or Units)<br>Purchased as<br>Part of Publicly<br>Announced Plans<br>or Programs | Maximum<br>Number (or<br>Approximate<br>Dollar Value of<br>Shares (or Units)<br>that May Yet Be<br>Purchased Under<br>the Plans or<br>Programs |
|--------------------------------------|---|--|--|--|
| July 5, 2015 - August 1, 2015(2)     |   | \$   |  |  |
| August 2, 2015 - August 29, 2015(2)  | 656,414   | \$ 15.64                                     | 656,414  | 2,022,753  |
| August 30, 2015 - October 3, 2015(2) | 368,586   | \$ 14.86                                     | 368,586  | 1,654,167  |
| <b>Totals</b>                        | <b>1,025,000</b>                                  | <b>\$ 15.36</b>                              | <b>1,025,000</b>   |  |

(1) The periods reported conform to our fiscal calendar which consists of two periods of four weeks and one period of five weeks in each fiscal quarter.

(2) Represents shares of our common stock repurchased in open market transactions under a share repurchase program approved by our Board of Directors in May 2008. A total of 4.0 million shares have been authorized for repurchase under this program and this program has no fixed expiration date. As of October 3, 2015, we had purchased a total of 2,345,833 shares and 1,654,167 shares remained available for purchase under the program.

Table of Contents

**ITEM 6. EXHIBITS**

| <b>Exhibit<br/>Number</b> | <b>Description of Exhibit</b>  |
|---------------------------|--|
| 3.1                       | Amended and Restated Bylaws of the Registrant, as adopted by the Board of Directors of the Registrant effective as of August 16, 2010 and amended on December 17, 2014 and August 18, 2015 (incorporated by reference to Exhibit 3.1 to Registrant's Current Report on Form 8-K filed with the Securities and Exchange Commission on August 24, 2015). |
| 31.1                      | Certification pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 (the Exchange Act).  |
| 31.2                      | Certification pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act.  |
| 32.1                      | Certification pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Exchange Act and 18 U.S.C. Section 1350.   |
| 32.2                      | Certification pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Exchange Act and 18 U.S.C. Section 1350.   |
| 101.INS                   | XBRL Instance Document.  |
| 101.SCH                   | XBRL Taxonomy Extension Schema Document.   |
| 101.CAL                   | XBRL Taxonomy Extension Calculation Linkbase Document.   |
| 101.DEF                   | XBRL Taxonomy Extension Definition Linkbase Document.  |
| 101.LAB                   | XBRL Taxonomy Extension Label Linkbase Document.   |
| 101.PRE                   | XBRL Taxonomy Extension Presentation Linkbase Document.  |

Table of Contents

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: November 12, 2015

NEWPORT CORPORATION

By:

*/s/ Charles F. Cargile*  
Charles F. Cargile,  
Senior Vice President, Chief Financial Officer and  
Treasurer (Principal Financial Officer and Duly  
Authorized Officer)

Table of Contents

**EXHIBIT INDEX**

| <b>Exhibit<br/>Number</b> | <b>Description of Exhibit</b>  |
|---------------------------|--|
| 3.1                       | Amended and Restated Bylaws of the Registrant, as adopted by the Board of Directors of the Registrant effective as of August 16, 2010 and amended on December 17, 2014 and August 18, 2015 (incorporated by reference to Exhibit 3.1 to Registrant's Current Report on Form 8-K filed with the Securities and Exchange Commission on August 24, 2015). |
| 31.1                      | Certification pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 (the Exchange Act).  |
| 31.2                      | Certification pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act.  |
| 32.1                      | Certification pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Exchange Act and 18 U.S.C. Section 1350.   |
| 32.2                      | Certification pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Exchange Act and 18 U.S.C. Section 1350.   |
| 101.INS                   | XBRL Instance Document.  |
| 101.SCH                   | XBRL Taxonomy Extension Schema Document.   |
| 101.CAL                   | XBRL Taxonomy Extension Calculation Linkbase Document.   |
| 101.DEF                   | XBRL Taxonomy Extension Definition Linkbase Document.  |
| 101.LAB                   | XBRL Taxonomy Extension Label Linkbase Document.   |
| 101.PRE                   | XBRL Taxonomy Extension Presentation Linkbase Document.  |